uniQure NV (LTS:0EE0)
$ 6.32 -0.73 (-10.35%) Market Cap: 312.44 Mil Enterprise Value: -55.20 Mil PE Ratio: 0 PB Ratio: 5.60 GF Score: 73/100

Uniqure NV at Barclays Global Healthcare Conference Transcript

Mar 13, 2019 / 05:35PM GMT
Release Date Price: $62
Gena Wang
Barclays Bank PLC, Research Division - Research Analyst

Good afternoon. My name is Gena Wang. I'm a SMID cap biotech analyst. It's my great pleasure to introduce our first speaker, Sander Van Deventer, Chief Scientific Officer of uniQure.

Sander Van Deventer
uniQure N.V. - Co-founder, Chief Scientific Officer & GM of Amsterdam

Thank you very much, Gena. It's a pleasure to be here at the conference. Thank you very much for the invitation. It's also a pleasure to introduce our company to you. I will be making some forward-looking statements, as you see here, during my presentation.

So uniQure is a gene therapy company, and the mission of uniQure is to deliver curative one-time therapies to transform the lives of patients, basically long-acting therapies. So the drivers behind our strategy, our pipelines, we have developed a pipeline of gene therapy candidates, which are focused on the liver and on the CNS. We'll discuss that in a little more detail. If you want to make a product, you need to have manufacturing. That's true for any drug,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot